CN115243699A - 分子导向系统肽及其用途 - Google Patents

分子导向系统肽及其用途 Download PDF

Info

Publication number
CN115243699A
CN115243699A CN202080069792.1A CN202080069792A CN115243699A CN 115243699 A CN115243699 A CN 115243699A CN 202080069792 A CN202080069792 A CN 202080069792A CN 115243699 A CN115243699 A CN 115243699A
Authority
CN
China
Prior art keywords
seq
mgs
nucleic acid
acid sequence
ch3co
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080069792.1A
Other languages
English (en)
Chinese (zh)
Inventor
凯瑟琳·C·布朗
迈克尔·麦圭尔
李顺子
因杜·维努戈帕尔
柯蒂斯·奥尔雷德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Publication of CN115243699A publication Critical patent/CN115243699A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080069792.1A 2019-10-01 2020-07-31 分子导向系统肽及其用途 Pending CN115243699A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908687P 2019-10-01 2019-10-01
US62/908,687 2019-10-01
PCT/US2020/044510 WO2021066931A1 (en) 2019-10-01 2020-07-31 Molecular guide system peptides and uses thereof

Publications (1)

Publication Number Publication Date
CN115243699A true CN115243699A (zh) 2022-10-25

Family

ID=75337452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080069792.1A Pending CN115243699A (zh) 2019-10-01 2020-07-31 分子导向系统肽及其用途

Country Status (6)

Country Link
US (1) US20220380764A1 (https=)
EP (2) EP4360655A3 (https=)
JP (2) JP2023503797A (https=)
CN (1) CN115243699A (https=)
AU (1) AU2020357455B2 (https=)
WO (1) WO2021066931A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240287148A1 (en) * 2021-07-15 2024-08-29 Cornell University Engineered biomolecules for nutrient reprogramming
US12516086B2 (en) 2021-12-21 2026-01-06 Sri International Dual targeting for cell-specific delivery to the central nervous system
WO2025006452A2 (en) * 2023-06-26 2025-01-02 Sri International NEU5GC-LEWISa-TARGETING MOLECULES AND USES THEREOF IN CANCER
WO2025240414A1 (en) * 2024-05-14 2025-11-20 Sri International Cardiomyocyte-specific molecular guidance system peptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089186A2 (en) * 2008-01-05 2009-07-16 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
WO2019014199A1 (en) * 2017-07-10 2019-01-17 Sri International PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCER
WO2019014190A1 (en) * 2017-07-10 2019-01-17 Brown Kathlynn C MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090110662A1 (en) * 2007-04-30 2009-04-30 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
PT3137605T (pt) * 2014-05-01 2020-12-18 Ionis Pharmaceuticals Inc Composições e métodos para modulação da expressão de angiopoietina de tipo 3
WO2019017199A1 (ja) * 2017-07-21 2019-01-24 株式会社豊田自動織機 正極活物質

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089186A2 (en) * 2008-01-05 2009-07-16 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
WO2019014199A1 (en) * 2017-07-10 2019-01-17 Sri International PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCER
WO2019014190A1 (en) * 2017-07-10 2019-01-17 Brown Kathlynn C MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANYI TAI ET AL: "Functional peptides for siRNA delivery", 《ADVANCED DRUG DELIVERY REVIEWS》, vol. 110, 28 February 2017 (2017-02-28), pages 157 - 168, XP085062904, DOI: 10.1016/j.addr.2016.08.004 *

Also Published As

Publication number Publication date
JP2023503797A (ja) 2023-02-01
EP4360655A2 (en) 2024-05-01
US20220380764A1 (en) 2022-12-01
AU2020357455A1 (en) 2022-04-14
EP4041272A1 (en) 2022-08-17
JP2025166082A (ja) 2025-11-05
EP4360655A3 (en) 2024-11-13
WO2021066931A1 (en) 2021-04-08
AU2020357455B2 (en) 2026-04-09
EP4041272A4 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
CN115243699A (zh) 分子导向系统肽及其用途
De Martini et al. Cell-penetrating peptides as valuable tools for nose-to-brain delivery of biological drugs
US8626452B2 (en) Compositions and methods for optimizing drug hydrophobicity and drug delivery to cells
US12576157B2 (en) Peptide saporin conjugate for the treatment of cancer
CN111278847B (zh) 分子导向系统肽及其用途
JP2024029097A (ja) ミニヌクレオソームコアタンパク質及び核酸送達における使用
Sheard et al. Peptide multimerization as leads for therapeutic development
CN115552013A (zh) 修饰的微核小体核心蛋白及其在核酸递送中的用途
JP2025176092A (ja) 中枢神経系への分子輸送系
Zhao et al. Zwitterionic internalizable peptide‐drug conjugates: tumor‐selective ultrafast uptake and transcytosis for enhanced antitumor therapy
JP7746284B2 (ja) 免疫治療薬に用いられるペプチド
US20210371478A1 (en) Generation of brain and spinal cord neurons, cardiac myocytes, and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptor
WO2026080440A1 (en) Mrna therapy for neurological disorders
WO2025109110A1 (en) Methods for identifying blood brain barrier peptide shuttles
Wallbrecher The journey of cell-penetrating peptides into cells-Studies on interactions with components of the plasma membrane and their impact on internalization

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination